Exploring the potential of cinnamic acid analogues in alzheimer’s disease
DARU Journal of Pharmaceutical Sciences · 03.03.2026 · 34 (1)
DOI: 10.1007/s40199-026-00593-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift DARU Journal of Pharmaceutical Sciences, online erschienen am 03.03.2026. Verfasst von Padmaja Patil und 2 weiteren Autor:innen. Beteiligte Einrichtung: SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, India. Hauptthemen laut MEDLINE: Alzheimer Disease, Cinnamates, Neuroprotective Agents, Antioxidants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 214 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Demenz
Abstract (Originalsprache)
BACKGROUND: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-β plaques and neurofibrillary tangles composed of hyperphosphorylated tau. Oxidative stress, exacerbated by mitochondrial dysfunction, metal dyshomeostasis, and impaired antioxidant defenses, plays a central role in synaptic dysfunction and cognitive decline. OBJECTIVES: This review evaluates the therapeutic potential of hydroxycinnamic acids as multi-target modulators of AD pathology, emphasizing mechanistic actions, structure–activity relationships, pharmacokinetic limitations, formulation strategies, and clinical evidence. METHODS: A narrative review was conducted using structured searches of PubMed, Scopus, Web of Science, and Google Scholar to identify relevant in vitro, in vivo, pharmacokinetic, formulation, and clinical studies on hydroxycinnamic acids in AD. RESULTS: Hydroxycinnamic acids, including ferulic acid, caffeic acid, chlorogenic acid, rosmarinic acid, and salvianolic acids, exhibit pleiotropic neuroprotective effects involving antioxidant, neuroinflammation, amyloid and tau modulation, and mitochondrial protection. Translation is limited by poor oral bioavailability, rapid metabolism, and restricted blood–brain barrier penetration. Nanoformulation and prodrug approaches show promise in improving CNS exposure in preclinical models. Clinical evidence remains limited, heterogeneous, and exploratory, with no compound demonstrating disease-modifying efficacy. CONCLUSION: Hydroxycinnamic acids hold promise as multi-target AD candidates. Clinical translation requires rigorous human PK studies, biomarker-driven trials, optimized formulations, and long-term safety evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, India.
- SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, India. arati.prabhu@bncp.ac.in.
Zitieren
APA
Patil, P., Jaiswal, S., & Prabhu, A. (2026). Exploring the potential of cinnamic acid analogues in alzheimer’s disease. DARU Journal of Pharmaceutical Sciences, 34(1). https://doi.org/10.1007/s40199-026-00593-2
Vancouver
Patil P, Jaiswal S, Prabhu A. Exploring the potential of cinnamic acid analogues in alzheimer’s disease. DARU Journal of Pharmaceutical Sciences. 2026;34(1). doi:10.1007/s40199-026-00593-2
BibTeX
@article{Patil2026,
author = {Patil, Padmaja and Jaiswal, Shreyash and Prabhu, Arati},
title = {Exploring the potential of cinnamic acid analogues in alzheimer’s disease},
journal = {DARU Journal of Pharmaceutical Sciences},
year = {2026},
volume = {34},
number = {1},
doi = {10.1007/s40199-026-00593-2}
}
EUVIMED